Insider filing
Traded Aug 31 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 12, 2026 · Filed Aug 12, 2026
The CEO of Pfizer paid $1M out of pocket for Pfizer shares. 2 other people at Pfizer bought some too, in the same month. Shares held went up 10% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$1,000,920
Shares × reported transaction price
$1M+
+9.7%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 3.6% of the CEO's reported total pay for fiscal 2025 ($27.6M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-12. The proxy names Bourla as CEO for that year. A size comparison, not a judgement
8 days after results of Aug 4, 2026, 83 days before results of Nov 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $26.31 on Aug 12, 2026, 11% above its 52-week low and 8% below its high, after a 9% rise over the previous 30 trading days
52-week range $23.60 (Sep 25, 2025) to $28.55 (Apr 1, 2026), 55% of the way up, from 251 adjusted closes. 30 trading days earlier: $24.08 on Jun 30, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Albert Bourla's first open-market purchase of PFE in filings since 2006
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.7% | −2.0% | +5.7% |
| 30 days | +3.4% | −2.2% | +5.6% |
| 90 days | +9.9% | −2.3% | +12.2% |
Past results only. Not a forecast.
Insider filing
Traded Aug 31 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 14 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Fund moves
91 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.